FindTrial
Sign In

Effect of Haloperidol and Risperidone to modify levels of markers of inflammation in blood in Schizophrenia Spectrum and other Psychotic Disorders

Effect of Haloperidol and Risperidone on inflammatory markers in Schizophrenia Spectrum and Other Psychotic Disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033890
Enrollment
40
Registered
2021-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F20-F29- Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders

Interventions

Intervention1: Haloperidol: First Generation Antipsychotic drug Dose- Therapeutic Range (2-20 mg/day) Frequency- per day single or divided doses Duration- 6 weeks Control Intervention1: Risperidone: S

Sponsors

Government Medical College and Hospital Sector Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients with a diagnosis of ‘Schizophrenia Spectrum and Other Psychotic disorder’ as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) given by American Psychiatric Association 2) Age group 18-65 years 3) Drug naïve patients 4) Any gender 5) Patients having the capacity (as per section 4 of the Mental Healthcare Act 2017) to give written consent or Nominated Representative (NR) agreeing to give written consent when patient does not have adequate capacity.

Exclusion criteria

Exclusion criteria: 1) Patients with substance abuse (in the past 6 months) except caffeine and nicotine 2) Patients with history of hypersensitivity to Haloperidol or Risperidone 3) Having infectious disease, physical injury and autoimmune diseases, using anti- inflammatory drugs, corticosteroids or antibiotics in the recent 4 weeks 4) Pregnant and lactating patient 5) Patients at high risk of suicide

Design outcomes

Primary

MeasureTime frame
Possible decrease in levels of inflammatory markers and symptoms in Schizophrenia Spectrum and Other Psychotic Disorders after 6 weeks of use of Antipsychotic Drugs (Haloperidol and Risperidone)Timepoint: Blood Investigations- at Baseline and 6 weeks Glasgow antipsychotic side effect scale- baseline and then every week till 6 weeks Positive and negative syndrome scale- Baseline, 2nd, 4th and 6th week—

Secondary

MeasureTime frame
Possible interventional modifications leading to improvement in prognosis of Schizophrenia Spectrum and Other Psychotic DisordersTimepoint: 2 years—

Countries

India

Contacts

Public ContactReema Bana

Government Medical College and Hospital, Sector-32, Chandigarh

Asthus10@gmail.com9646121613

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026